ReviewFrontiers in microbiology2021
Current Status of Chikungunya in India.
Review in Frontiers in microbiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 71 citations in OpenAlex.
- Resurgence of Chikungunya in Thailand.IJID regions · 2026Article
- Article
- Molecular Evolution of the Chikungunya VirusViruses · 2026Article
- Genomic and Immunological Insights Into Chikungunya Virus Evolution During the 2018 and 2023-24 Outbreaks in Southern India.Journal of medical virology · 2026Article
- Pathogenesis of Chronic Arthritis Due to Chikungunya Virus and Advances in Vaccine Development.Viruses · 2026Review
- Resurgent threat in a changing climate: A 20-year bibliometric analysis of global Chikungunya research evolution and pandemic preparedness.PLoS neglected tropical diseases · 2026Article
- If Diffuse Hyperpigmentation is Present with Signs of Sepsis in a Newborn, Think of Congenital Chikungunya.Dermatology practical & conceptual · 2026Article
- The construction of CD8+ T cell-associated molecular subtypes in esophageal squamous cell carcinoma reveals tumor heterogeneity, tumor microenvironment, and immunotherapy.Frontiers in immunology · 2026Article
- Competitive Viral Interference Controls Arbovirus Co-Transmission in Aedes aegypti.Scientific reports · 2025Article
- Spatial epidemiology of dengue and chikungunya in Karnataka using GIS-based analysis.Global health action · 2025Article
- Diagnostic utility of real-time RT-PCR for chikungunya virus detection in the acute phase of infection: a retrospective study.Annals of medicine · 2025Article
- The possibly neglected victims: Re-examining the involvement of children in the chikungunya epidemic.Pediatric investigation · 2025Article
- Clinical and molecular epidemiology of chikungunya outbreaks during 2019-2022 in India.Scientific reports · 2025Article
- Proteomic Analysis of CHIKV-nsP3 Host Interactions in Liver Cells Identifies Novel Interacting Partners.International journal of molecular sciences · 2025Article
- A comprehensive overview of the burden, prevention, and therapeutic aspects of arboviral diseases in India.Communications medicine · 2025Review
- Microbiological Investigations for Chikungunya Virus in Children With Acute Encephalitis Syndrome in a Non-Outbreak Setting in Southern India.Journal of medical virology · 2025Article
- Beyond the Bite: Detailed findings on Chikungunya and Dengue co-detection in Punjab, North India - clinical insights and diagnostic challenges.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2024Article
- Development of Multiplex Molecular Assays for Simultaneous Detection of Dengue Serotypes and Chikungunya Virus for Arbovirus Surveillance.Current issues in molecular biology · 2024Article
- Molecular identification and phylogenetic analysis of chikungunya virus among dengue-negative patients in Kolkata, India.PloS one · 2024Article
- Cytokine profile, neutralisation potential and viral replication dynamics in sera of chikungunya patients in India: a cross-sectional study.The Lancet regional health. Southeast Asia · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chikungunya fever (CHIKF) is an arbovirus disease caused by chikungunya virus (CHIKV), an alphavirus of Togaviridae family. Transmission follows a human-mosquito-human cycle starting with a mosquito bite. Subsequently, symptoms develop after 2-6 days of incubation, including high fever and severe arthralgia. The disease is self-limiting and usually resolve within 2 weeks. However, chronic disease can last up to several years with persistent polyarthralgia. Overlapping symptoms and common vector with dengue and malaria present many challenges for diagnosis and treatment of this disease. CHIKF was reported in India in 1963 for the first time. After a period of quiescence lasting up to 32 years, CHIKV re-emerged in India in 2005. Currently, every part of the country has become endemic for the disease with outbreaks resulting in huge economic and productivity losses. Several mutations have been identified in circulating strains of the virus resulting in better adaptations or increased fitness in the vector(s), effective transmission, and disease severity. CHIKV evolution has been a significant driver of epidemics in India, hence, the need to focus on proper surveillance, and implementation of prevention and control measure in the country. Presently, there are no licensed vaccines or antivirals available; however, India has initiated several efforts in this direction including traditional medicines. In this review, we present the current status of CHIKF in India.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.